Selective VEGFR Inhibitors for Anticancer Therapeutics in Clinical Use and Clinical Trials

Title:Selective VEGFR Inhibitors for Anticancer Therapeutics in Clinical Use and Clinical Trials

Volume: 18 Issue: 20

Author(s): Cunlong Zhang, Chunyan Tan, Huaiwei Ding, Tian Xin and Yuyang Jiang

Affiliation:

Keywords: Selective, VEGFR inhibitor, anticancer, angiogenesis, vasculogenesis, tumor growth, metastasis, clinical trials, signaling pathways, growth factors

Abstract: Angiogenesis and vasculogenesis, regulated by VEGF/VEGFR signaling pathways, play key roles in tumor growth and metastasis. Selective inhibition of VEGFR kinase has been explored as a highly successful clinical strategy in cancer treatment. A number of VEGFR inhibitors have been approved in clinical use and many more are in various stages of drug development. This paper reviews selective small-molecule VEGFR inhibitors in clinical uses and in clinical trials, with particular focus on in vitro, in vivo and clinical trial results of these inhibitors. The VEGF/VEGFR genes and signaling pathways involved in tumor angiogenesis, and the strategies for accessing and improving the therapeutic efficacy of VEGFR inhibitors are also discussed.

Cite this article as:

Zhang Cunlong, Tan Chunyan, Ding Huaiwei, Xin Tian and Jiang Yuyang, Selective VEGFR Inhibitors for Anticancer Therapeutics in Clinical Use and Clinical Trials, Current Pharmaceutical Design 2012; 18 (20) . https://dx.doi.org/10.2174/138161212800672732